Usefulness of 18F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer. Issue 4 (9th April 2023)
- Record Type:
- Journal Article
- Title:
- Usefulness of 18F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer. Issue 4 (9th April 2023)
- Main Title:
- Usefulness of 18F-FDG PET/computed tomography metabolic parameters in predicting sarcopenia and prognosis of treatment-naive patients with non-small cell lung cancer
- Authors:
- Li, Dongjiang
Tan, Xiaoyue
Yuan, Hui
Yao, Xinchao
Sun, Xiaolin
He, Li
Jiang, Lei - Abstract:
- Abstract : Purpose: Sarcopenia tremendously impacts the quality of life but remains debatable in prognostication in treatment-naive patients with non-small cell lung cancer (NSCLC). Hence, this study aimed to find a clinically feasible approach using 18 F-FDG PET/computed tomography (CT) imaging parameters and clinical characteristics to predict sarcopenia and determine independent prognostic factors. Methods: Clinical characteristics and 18 F-FDG PET/CT metabolic parameters, including maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of primary tumor (SUVmax_P, MTV_P, and TLG_P) and combination of whole-body lesions (MTV_C and TLG_C) were collected in 344 treatment-naive patients with NSCLC. Skeletal muscle index at the third lumbar vertebra was calculated to determine sarcopenia. SUVmax of the psoas major muscle (SUVmax_M) was measured at the third lumbar vertebra as well. The diagnostic endpoint is the probability of sarcopenia, and the survival endpoints include progression-free survival (PFS) and overall survival (OS). Results: Among 344 patients with NSCLC there were 271 patients with adenocarcinoma and 73 with squamous cell carcinoma (SCC). One hundred forty-seven patients (42.7%) were diagnosed with sarcopenia. Higher age, male, lower BMI, SCC, and lower SUVmax_M were correlated with a higher incidence of sarcopenia ( P < 0.05), while age, sex and SUVmax_M were independently predictive of sarcopenia. Multivariate Cox-regressionAbstract : Purpose: Sarcopenia tremendously impacts the quality of life but remains debatable in prognostication in treatment-naive patients with non-small cell lung cancer (NSCLC). Hence, this study aimed to find a clinically feasible approach using 18 F-FDG PET/computed tomography (CT) imaging parameters and clinical characteristics to predict sarcopenia and determine independent prognostic factors. Methods: Clinical characteristics and 18 F-FDG PET/CT metabolic parameters, including maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of primary tumor (SUVmax_P, MTV_P, and TLG_P) and combination of whole-body lesions (MTV_C and TLG_C) were collected in 344 treatment-naive patients with NSCLC. Skeletal muscle index at the third lumbar vertebra was calculated to determine sarcopenia. SUVmax of the psoas major muscle (SUVmax_M) was measured at the third lumbar vertebra as well. The diagnostic endpoint is the probability of sarcopenia, and the survival endpoints include progression-free survival (PFS) and overall survival (OS). Results: Among 344 patients with NSCLC there were 271 patients with adenocarcinoma and 73 with squamous cell carcinoma (SCC). One hundred forty-seven patients (42.7%) were diagnosed with sarcopenia. Higher age, male, lower BMI, SCC, and lower SUVmax_M were correlated with a higher incidence of sarcopenia ( P < 0.05), while age, sex and SUVmax_M were independently predictive of sarcopenia. Multivariate Cox-regression analysis revealed that BMI, advanced stage and TLG_C were independent predictors of PFS and OS, while sex was independently predictive of OS. Conclusions: The incidence of sarcopenia increased with declining SUVmax of muscle. BMI, tumor stage, and TLG_C, but not sarcopenia, were found independently predictive of both PFS and OS. … (more)
- Is Part Of:
- Nuclear medicine communications. Volume 44:Issue 4(2023)
- Journal:
- Nuclear medicine communications
- Issue:
- Volume 44:Issue 4(2023)
- Issue Display:
- Volume 44, Issue 4 (2023)
- Year:
- 2023
- Volume:
- 44
- Issue:
- 4
- Issue Sort Value:
- 2023-0044-0004-0000
- Page Start:
- 309
- Page End:
- 317
- Publication Date:
- 2023-04-09
- Subjects:
- 18F-FDG PET/computed tomography -- metabolic parameters -- non-small cell lung cancer -- prognosis -- sarcopenia
Nuclear medicine -- Periodicals
616.07575 - Journal URLs:
- http://journals.lww.com/nuclearmedicinecomm/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
http://www.lww.com/Product/0143-3636 ↗ - DOI:
- 10.1097/MNM.0000000000001669 ↗
- Languages:
- English
- ISSNs:
- 0143-3636
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6180.923000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26095.xml